Wolf

Elon fired 80% of Dorsey's last company before chatGPT was even out and it thrived. may be more of a bloat thing than an AI thing

What if I told you that laying off 4,000 employees should've already been done regardless of advancements in AI? $XYZ, like many tech companies during Covid, over-hired. But saying AI is replacing seats is a nicer way to deliver a pink-slip than admitting to corporate mistakes

I don't care for the Olympics.

.. will certainly want to use the more powerful QNCX therapy. This degree of confidence is likely why certain whales are short puts with only a few month DTE. You’re not short puts in a small-cap biotech unless you have quite the confidence. I can begin to understand why.

There is a place for IntraBio’s line of treatment. The two treatments can work concomitantly and I’m sure they will. IntraBio can help ease AT symptoms at any age which is great news for AT sufferers, but those parents of the age 6-9 children diagnosed with the disease ...

What’s interesting about the $QNCX story is that we already know the drug works. Steroids, in this case dexamethasone, is a tried therapy for AT. So this isn’t a, “Will it or won’t it?” story of biotech, per sè. We already know it does. The real question is that of repeatability.

Of course not because it can be tremendously powerful in the early stages. So even though the overall survival of the population may not be substantial, for certain segments of the population (ie. those using treatment in the earlier stages), it can be life-changing.

Some more bullish $QNCX tidbits. Take a look of who's been adding in the past few months in anticipation of Phase 3. Some very sharp managers, including Millennium and anchor investor, Nantahala. Prominent biotech multi-baggers in the past for both these managers.

One month to go and I expect very positive results. Remember this opens up many other diseases that this platform will be able to go after. This is as much about a platform as it is this one disease. That isn’t priced into the stock at all. Positive data on this disease pushes this over $20, then other indications started getting priced in as potential and that pushes us much much higher

@Octopusking77 4) What makes QNCX particularly compelling is the potential beyond AT – to treat other rare and difficult diseases. With their patented technology w/ the AIDE machine, this is exciting from a valuation perspective. DMD is up next and trials begin in 2H 26. Cheers!

@Octopusking77 3) QNCX has an ATM offering filed w/ the SEC, which they’ll use as soon as they release Phase 3. Will fund them to the filing, commercialization and first revenue.

Bullish $QNCX. Some perceive IntraBio's recent phase 3 as a threat to QNCX's upcoming top-line results. I would argue that knowing IntraBio's results, the forthcoming QNCX top-line has been de-risked.

CEO Dirk Thye recently received 1 million in options (4 year vest, strike of $3.08 - ATM). Board members have opted to receive retainers and compensation in all options, a break from the past where it was a mix of options + cash. Incentives are aligned here.

.. we get a powerful result. I can see why management is so bullish. It would be hard to argue why a clinician would not be willing to offer a therapy with nearly 3x the potency for a young family devastated by the diagnosis of AT.

And of course, a lot of value in Quince is from its AIDE platform. Not only will they be set to transform AT therapy, they can use their patented platform technology to start gaining approval for other rare and intractable diseases, DMD, of course being next up.